{"protocolSection": {"identificationModule": {"nctId": "NCT03654976", "orgStudyIdInfo": {"id": "MT-11"}, "secondaryIdInfos": [{"id": "2016-004363-39", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "ALK-Abell\u00f3 A/S", "class": "INDUSTRY"}, "briefTitle": "Mite Asthma Pediatric Immunotherapy Trial", "officialTitle": "A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Children and Adolescents (5-17 Years) With HDM Allergic Asthma", "acronym": "MAPIT"}, "statusModule": {"statusVerifiedDate": "2023-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-02-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-05-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-05-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-08-24", "studyFirstSubmitQcDate": "2018-08-30", "studyFirstPostDateStruct": {"date": "2018-08-31", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-05-26", "resultsFirstSubmitQcDate": "2023-10-17", "resultsFirstPostDateStruct": {"date": "2023-10-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-10-17", "lastUpdatePostDateStruct": {"date": "2023-10-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "ALK-Abell\u00f3 A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma worsening.", "detailedDescription": "The trial aims to demonstrate efficacy of the HDM SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with HDM allergic asthma based on clinically relevant asthma exacerbations.\n\nAdditionally, the trial will investigate if the treatment has an effect on asthma symptoms including nightly awakenings due to asthma, asthma medication use, asthma control, lung function, allergic rhinitis and allergic rhinoconjunctivitis.\n\nFinally, quality of life (QoL) for subjects and caregivers will be measured.\n\nThe trial is a randomised, parallel-group, double-blind, placebo-controlled multi-national phase III trial conducted in Europe and North America. The treatment period will be approximately 2 years. Subjects will receive a written asthma action plan."}, "conditionsModule": {"conditions": ["Allergic Asthma Due to Dermatophagoides Farinae", "Allergic Asthma Due to Dermatophagoides Pteronyssinus", "Allergic Rhinitis Due to House Dust Mite"], "keywords": ["Allergic asthma, allergic rhinitis, HDM, pediatric"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Parallel-group", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "Double-blind", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 533, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Active treatment", "type": "EXPERIMENTAL", "description": "Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet", "interventionNames": ["Biological: HDM SLIT-tablet"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Subject's ICS or ICS/LABA background medication plus placebo oral tablet", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "HDM SLIT-tablet", "description": "Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)", "armGroupLabels": ["Active treatment"], "otherNames": ["Acarizax", "Odactra"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo sublingual tablet, for daily administration (1 tablet per day)", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annualized Rate of Clinically Relevant Asthma Exacerbations", "description": "The primary endpoint of the trial was the annualized rate of clinically relevant asthma exacerbations calculated as the number of exacerbations per year per participant during the efficacy evaluation period of 20 months. A clinically relevant asthma exacerbation had to be medically confirmed and was defined as asthma worsening leading to at least 1 of the following criteria:\n\n* Doubling of ICS dose compared to background treatment\n* Systemic corticosteroids for treatment of asthma symptoms for at least 3 days\n* Emergency room visit due to asthma, requiring systemic corticosteroids\n* Hospitalization for more than 12 hours due to asthma, requiring treatment with systemic corticosteroids\n\nThe outcome measure (by treatment group) is an adjusted annualized rate of clinically relevant asthma exacerbations.", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)"}], "secondaryOutcomes": [{"measure": "Proportion of Days With Nocturnal Awakenings Due to Asthma Requiring SABA Rescue Medication", "description": "The days with nocturnal awakenings due to asthma requiring SABA rescue medication were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months. The proportion of days with nocturnal awakenings due to asthma requiring SABA was presented on a range from 0 to 1 (1 indicating that all days in the eDiary period were with nocturnal awakenings due to asthma requiring SABA rescue medication). The efficacy assessment was based on data collected over the 20 months efficacy assessment period.\n\nThe outcome measure (by treatment group) is an estimated proportion of days with nocturnal awakenings due to asthma requiring SABA rescue medication.", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)"}, {"measure": "Proportions of Days With SABA Use", "description": "The days with SABA use were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months. The proportion of days with SABA use was presented on a range from 0 to 1 (1 indicating that all days in the eDiary period were with SABA use). The efficacy assessment was based on data collected over the 20 months efficacy assessment period.\n\nThe outcome measure (by treatment group) is an estimated proportion of days with SABA use.", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)"}, {"measure": "Percentage Predicted FEV1", "description": "The outcome measure (by treatment) is an average of the percentage predicted FEV1 measured at visits 5 to 11 (every 4 months during the 20 months efficacy assessment period), analyzed using MMRM (mixed-effect model repeated measurement).\n\nFEV1 (forced expired volume in 1 second) is assessed by use of spirometry and is a measure for lung function. Percentage predicted FEV1 is derived from the predicted FEV1, which is the expected value of FEV1 for a person of a certain age, race, height and gender with healthy lungs.", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)"}, {"measure": "Global Evaluation of Allergic Asthma as Having an Improved Outcome", "description": "At the end of trial visit, the subject was asked, when compared to their asthma before IMP treatment, how they felt overall. Subjects who answered 'much better' or 'better' were categorized as having improved allergic asthma. At the end of trial visit, subjects had been treated for 24-30 months (including a 4-10 months treatment initiation and maintenance period).\n\nThe outcome measure (by treatment) is an adjusted odds of experiencing improved allergic asthma.", "timeFrame": "Assessment done at the end of trial visit (after 24-30 months of treatment)"}, {"measure": "Global Evaluation of Allergic Rhinitis as Having an Improved Outcome", "description": "At the end of trial visit, the subject was asked, when compared to their rhinitis before IMP treatment, how they felt overall. Subjects who answered 'much better' or 'better' were categorized as having improved allergic rhinitis. At the end of trial visit, subjects had been treated for 24-30 months (including a 4-10 months treatment initiation and maintenance period).\n\nThe outcome measure (by treatment) is an adjusted odds of experiencing improved allergic rhinitis.", "timeFrame": "Assessment done at the end of trial visit (after 24-30 months of treatment)"}], "otherOutcomes": [{"measure": "Allergic Rhinitis Symptoms", "description": "Allergic rhinitis symptoms were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months, for up to 24-30 months.", "timeFrame": "The efficacy assessment period for the endpoint started 4 months after treatment initiation and lasted until the end of the trial or discontinuation of treatment (up to 24-30 months of treatment)."}, {"measure": "Allergic Rhinitis Medication Use", "description": "Allergic rhinitis medication use were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months, for up to 24-30 months.", "timeFrame": "The efficacy assessment period for the endpoint started 4 months after treatment initiation and lasted until the end of the trial or discontinuation of treatment (up to 24-30 months of treatment)."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent\n* Male or female of any race/ethnicity aged 5-17 years\n* A female subject of childbearing potential must have a negative pregnancy test and be willing to practise appropriate contraceptive methods\n* A clinical history of HDM allergic asthma\n* Use of low daily dose of ICS plus LABA or medium/high daily dose of ICS with or without LABA for the control of asthma symptoms\n* A clinical history of asthma exacerbations in the past two years\n* One or more of the following within the past 4 weeks prior to randomisation:\n\n  * Daytime asthma symptoms more than twice/week\n  * Any nocturnal awakening due to asthma\n  * SABA rescue medication needed for treatment of asthma symptoms\n  * Any activity limitation due to asthma\n* Lung function measured by FEV1 \u2265 70% of predicted value or according to local requirements\n* Clinical history of HDM AR within the last year prior to randomisation\n* An average TCRS\\>0 during the baseline period\n* Positive specific IgE (defined as \u2265class 2, \u22650.70 kU/l) against D. pteronyssinus and/or D. farinae at screening\n* Positive SPT to D. pteronyssinus and/or D. farinae at screening\n* Subject willing and able to comply with trial protocol\n\nExclusion Criteria:\n\n* Is sensitised and regularly exposed to animal dander, molds, and/or cockroach or other perennial allergen\n* Has experienced a life-threatening asthma attack\n* Within the last month before the randomisation visit (visit 3), has had an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalisation, or treatment with systemic corticosteroids\n* Within the last 3 months before the randomisation visit (visit 3) while on high dose ICS treatment, has had an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalisation, or treatment with systemic corticosteroids\n* Any SLIT or SCIT treatment with D. pteronyssinus or D. farinae within the previous 12 months\n* Ongoing treatment with any allergy immunotherapy product\n* Any clinically relevant condition or chronic disease incl. malignancy that in the opinion of the investigator would interfere with the trial evaluations or the safety of the subject\n* Has a diagnosis of eosinophilic oesophagitis\n* A relevant history of systemic allergic reactions\n* Ongoing treatment with OCS\n* Treatment with restricted and prohibited concomitant medication\n* Treatment with an investigational drug within 30 days/5 half-lives of the drug (which ever longest) prior to screening\n* A history of allergy, hypersensitivity or intolerance to any of the excipients or active substance of the IMP (except D. pteronyssinus and D. farinae) or to any excipient of the rescue medication provided in this trial\n* A business or personal relationship with trial staff or sponsor who is directly involved with the conduct of the trial\n* A history of alcohol or drug abuse\n* Has previously been randomised into this trial, is participating in this trial at another investigational site or is participating or planning to participate in any other clinical trial during the duration of this trial\n* Has a history or current evidence of any condition, treatment, laboratory values out of range or other circumstance that in the opinion of the investigator are clinically relevant and might expose the subject to risk by participating in the trial, confound the results of the trial, or interfere with the subject's participation for the full duration of the trial\n* Has a condition or treatment that increase the risk of the subject developing severe adverse reactions after adrenaline/epinephrine administration\n* Is unable to or will not comply with the use of adrenaline/epinephrine auto-injectors for countries where this is a regulatory requirement", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "5 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Graham Roberts, MD", "affiliation": "University Hospital Southampton NHS Foundation", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Miami Clinical Research", "city": "Miami", "state": "Florida", "zip": "33155", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Columbus Regional Research Institute", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Respiratory Medicine Research Institute of MI", "city": "Ypsilanti", "state": "Michigan", "zip": "48197", "country": "United States", "geoPoint": {"lat": 42.24115, "lon": -83.61299}}, {"facility": "Private Clinic", "city": "Bangor", "state": "Pennsylvania", "zip": "04401", "country": "United States", "geoPoint": {"lat": 40.86565, "lon": -75.20657}}, {"facility": "Allergy Consultants", "city": "Verona", "state": "Pennsylvania", "zip": "07044", "country": "United States", "geoPoint": {"lat": 40.50646, "lon": -79.8431}}, {"facility": "TTS research", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "STAAMP Research", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "MHAT", "city": "Plovdiv", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "UMBAL \"St. Georgy\"", "city": "Plovdiv", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "SHATPPD", "city": "Ruse", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Medical Center-1-Sevlievo EOOD", "city": "Sevlievo", "country": "Bulgaria", "geoPoint": {"lat": 43.02583, "lon": 25.11361}}, {"facility": "Alitera-Med-Medical Center EOOD", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "MBAL Tokuda Hospital Sofia", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Medical Center Excelsior", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "DCC Ritam 2010", "city": "Stara Zagora", "country": "Bulgaria", "geoPoint": {"lat": 42.43278, "lon": 25.64194}}, {"facility": "Hopital Augustin Morvan", "city": "Brest", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Centre Hospitalier Universitaire de Caen", "city": "Caen", "country": "France", "geoPoint": {"lat": 49.18585, "lon": -0.35912}}, {"facility": "Centre hospitalier intercommunal", "city": "Cr\u00e9teil", "country": "France", "geoPoint": {"lat": 48.78333, "lon": 2.46667}}, {"facility": "H\u00f4pital Jeanne de Flandre", "city": "Lille Cedex", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Groupe hospitalier Armand Trousseau - La Roche Guyon", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Kinderarzt-Praxis Bramsche", "city": "Bramsche", "country": "Germany", "geoPoint": {"lat": 52.40881, "lon": 7.97288}}, {"facility": "Kinderarztpraxis Ludwigsfelde", "city": "Ludwigsfelde", "country": "Germany", "geoPoint": {"lat": 52.30322, "lon": 13.25405}}, {"facility": "Kinderarztpraxis", "city": "Wuppertal", "country": "Germany", "geoPoint": {"lat": 51.27027, "lon": 7.16755}}, {"facility": "Bajai Szent R\u00f3kus K\u00f3rh\u00e1z", "city": "Baja", "country": "Hungary", "geoPoint": {"lat": 46.17496, "lon": 18.95639}}, {"facility": "Heim Pal Children's Hospital", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Semmelweis Egyetem", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Kanizsai Dorottya Korhaz", "city": "Nagykanizsa", "country": "Hungary", "geoPoint": {"lat": 46.45347, "lon": 16.99104}}, {"facility": "Szent Istv\u00e1n Rendel\u0151 \u00e9s Patika", "city": "R\u00e1ckeve", "country": "Hungary", "geoPoint": {"lat": 47.16095, "lon": 18.94478}}, {"facility": "Aranyklinika Kft", "city": "Szeged", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "NZOZ E-Vita", "city": "Bia\u0142ystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny", "city": "Bia\u0142ystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Specjalistyczna Praktyka Lekarska", "city": "Katowice", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Centrum Medyczne PROMED", "city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Centrum Nowoczesnych Terapii", "city": "Krak\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "ALERGOTEST s.c. Specjalistyczne Centrum Medyczne", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Uniwersytecki Szpital Dzieciecy w Lublinie", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Ostrowieckie Centrum Medyczne S.C.", "city": "Ostrowiec \u015awi\u0119tokrzyski", "country": "Poland", "geoPoint": {"lat": 50.92936, "lon": 21.38525}}, {"facility": "Prywatny Gabinet Lekarski", "city": "Rzesz\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"facility": "NSZOZ Puls", "city": "Skar\u017cysko-Kamienna", "country": "Poland", "geoPoint": {"lat": 51.11311, "lon": 20.87162}}, {"facility": "ETG Skierniewice", "city": "Skierniewice", "country": "Poland", "geoPoint": {"lat": 51.95485, "lon": 20.15837}}, {"facility": "ALERGO-MED Specjalistyczna", "city": "Tarn\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Dobrostan", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Specjalist.", "city": "Zabrze", "country": "Poland", "geoPoint": {"lat": 50.32492, "lon": 18.78576}}, {"facility": "WWCOiT", "city": "\u0141\u00f3d\u017a", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Kazan State Medical University 138", "city": "Kazan", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "First Moscow State Medical University", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Clinical and Diagnostic Centre \"Zdorovie\"", "city": "Rostov-on-Don", "country": "Russian Federation", "geoPoint": {"lat": 47.23135, "lon": 39.72328}}, {"facility": "Rayzan Regional Children Hospital", "city": "Ryazan", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"facility": "LLC Kurator", "city": "Saint Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City children's polyclinic #35", "city": "Saint-Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GBUZ \"Children Municipal Polyclinic #45\"", "city": "Saint-Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "LLC ArsVite Severo-Zapad", "city": "Saint-Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GBUZ \"Samarskiy oblastnoy detskiy sanatoriy \"Yunost\" 9-proseka", "city": "Samara", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "LLC 'ArsVitae Samara'", "city": "Samara", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "Siberian State Medical University", "city": "Tomsk", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Hospital Universitari Germans Trias i Pujol", "city": "Badalona", "country": "Spain", "geoPoint": {"lat": 41.45004, "lon": 2.24741}}, {"facility": "Hospital Universitario Vall d'Hebr\u00f3n", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Hospital Regional Universitario de M\u00e1laga", "city": "M\u00e1laga", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Hospital de Sagunto", "city": "Sagunto", "country": "Spain", "geoPoint": {"lat": 39.68333, "lon": -0.26667}}, {"facility": "Hospital Universitario Marqu\u00e9s de Valdecilla", "city": "Santander", "country": "Spain", "geoPoint": {"lat": 43.46472, "lon": -3.80444}}, {"facility": "Hospital de Conxo", "city": "Santiago De Compostela", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Hospital de la Plana", "city": "Villarreal", "country": "Spain", "geoPoint": {"lat": 39.9383, "lon": -0.10087}}, {"facility": "Royal Manchester Children's Hospital - Paediatrics Oxford Road", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Southampton General Hospital", "city": "Southampton", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The trial had randomized participants from 64 sites in 9 countries (Bulgaria, France, Germany, Hungary, Poland, Russia, Spain, United Kingdom, US).", "groups": [{"id": "FG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) or medium/high dose ICS with or without LABA, reliever asthma medication of short-acting beta-agonist (SABA) as needed plus 1 daily house dust mite (HDM) sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "FG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "270"}, {"groupId": "FG001", "numSubjects": "263"}]}, {"type": "Completed IMP", "achievements": [{"groupId": "FG000", "numSubjects": "239"}, {"groupId": "FG001", "numSubjects": "242"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "264"}, {"groupId": "FG001", "numSubjects": "260"}]}, {"type": "Safety Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "270"}, {"groupId": "FG001", "numSubjects": "263"}]}, {"type": "COMPLETED", "comment": "Completed trial", "achievements": [{"groupId": "FG000", "numSubjects": "241"}, {"groupId": "FG001", "numSubjects": "245"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "18"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Reason stated as 'Other' in CRF", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants", "groups": [{"id": "BG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "BG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "270"}, {"groupId": "BG001", "value": "263"}, {"groupId": "BG002", "value": "533"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "270"}, {"groupId": "BG001", "value": "263"}, {"groupId": "BG002", "value": "533"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.6", "spread": "3.4"}, {"groupId": "BG001", "value": "10.6", "spread": "3.3"}, {"groupId": "BG002", "value": "10.6", "spread": "3.4"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Children (5-11 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "162"}, {"groupId": "BG001", "value": "154"}, {"groupId": "BG002", "value": "316"}]}]}, {"title": "Adolescents (12-17 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "217"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "182"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "182"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "351"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "44"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "238"}, {"groupId": "BG001", "value": "224"}, {"groupId": "BG002", "value": "462"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "27"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "11"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "259"}, {"groupId": "BG001", "value": "254"}, {"groupId": "BG002", "value": "513"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Bulgaria", "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "65"}]}]}, {"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "25"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "11"}]}]}, {"title": "Hungary", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "146"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "291"}]}]}, {"title": "Russia", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "38"}]}]}, {"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "36"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "26"}]}]}]}, {"title": "Region", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "West (DEU, ESP, FRA, GRB, USA)", "categories": [{"measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "102"}]}]}, {"title": "Central (POL)", "categories": [{"measurements": [{"groupId": "BG000", "value": "146"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "291"}]}]}, {"title": "East (BGR, HUN, RUS)", "categories": [{"measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "140"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annualized Rate of Clinically Relevant Asthma Exacerbations", "description": "The primary endpoint of the trial was the annualized rate of clinically relevant asthma exacerbations calculated as the number of exacerbations per year per participant during the efficacy evaluation period of 20 months. A clinically relevant asthma exacerbation had to be medically confirmed and was defined as asthma worsening leading to at least 1 of the following criteria:\n\n* Doubling of ICS dose compared to background treatment\n* Systemic corticosteroids for treatment of asthma symptoms for at least 3 days\n* Emergency room visit due to asthma, requiring systemic corticosteroids\n* Hospitalization for more than 12 hours due to asthma, requiring treatment with systemic corticosteroids\n\nThe outcome measure (by treatment group) is an adjusted annualized rate of clinically relevant asthma exacerbations.", "populationDescription": "Participant from the full analysis set with observations in the efficacy assessment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbations per year per participant", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)", "groups": [{"id": "OG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "OG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "252"}, {"groupId": "OG001", "value": "257"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.18", "lowerLimit": "0.13", "upperLimit": "0.25"}, {"groupId": "OG001", "value": "0.21", "lowerLimit": "0.15", "upperLimit": "0.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The number of clinically relevant asthma exacerbations was analyzed using a negative binomial regression model with a log-link function and the logarithm of the time in years in the efficacy period as offset. The model included treatment, age group (\\<12 years, \\>=12 years) and region (west: DEU, ESP, FRA, GBR and USA; central: POL; east: BGR, HUN and RUS) as fixed factors. No missing data approach was applied.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5412", "statisticalMethod": "Negative binomial regression", "paramType": "Rate ratio", "paramValue": "0.89", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.60", "ciUpperLimit": "1.31", "estimateComment": "12 SQ-HDM SLIT-tablet as the numerator and placebo SLIT-tablet as the denominator."}]}, {"type": "SECONDARY", "title": "Proportion of Days With Nocturnal Awakenings Due to Asthma Requiring SABA Rescue Medication", "description": "The days with nocturnal awakenings due to asthma requiring SABA rescue medication were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months. The proportion of days with nocturnal awakenings due to asthma requiring SABA was presented on a range from 0 to 1 (1 indicating that all days in the eDiary period were with nocturnal awakenings due to asthma requiring SABA rescue medication). The efficacy assessment was based on data collected over the 20 months efficacy assessment period.\n\nThe outcome measure (by treatment group) is an estimated proportion of days with nocturnal awakenings due to asthma requiring SABA rescue medication.", "populationDescription": "Participants from the full analysis set with observations in the efficacy assessment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Proportion of days with awakenings", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)", "groups": [{"id": "OG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "OG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "253"}, {"groupId": "OG001", "value": "259"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0147", "lowerLimit": "0.0093", "upperLimit": "0.0233"}, {"groupId": "OG001", "value": "0.0190", "lowerLimit": "0.0126", "upperLimit": "0.0287"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A marginal logistic regression model with a generalized estimating approach was analyzed using treatment, visit, treatment\\*visit, age group (\\<12 years, \\>=12 years) and region (west: DEU, ESP, FRA, GBR and USA; central: POL; east: BGR, HUN and RUS) as fixed factors. Baseline visit was included as a covariate. No missing data approach was applied.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4156", "statisticalMethod": "Marginal logistic regression", "paramType": "Odds Ratio (OR)", "paramValue": "0.7713", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.41", "ciUpperLimit": "1.44", "estimateComment": "12 SQ-HDM SLIT-tablet as the numerator and placebo SLIT-tablet as the denominator."}]}, {"type": "SECONDARY", "title": "Proportions of Days With SABA Use", "description": "The days with SABA use were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months. The proportion of days with SABA use was presented on a range from 0 to 1 (1 indicating that all days in the eDiary period were with SABA use). The efficacy assessment was based on data collected over the 20 months efficacy assessment period.\n\nThe outcome measure (by treatment group) is an estimated proportion of days with SABA use.", "populationDescription": "Participants from the full analysis set with observations in the efficacy assessment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Proportion of days with SABA use", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)", "groups": [{"id": "OG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "OG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "253"}, {"groupId": "OG001", "value": "259"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0943", "lowerLimit": "0.0694", "upperLimit": "0.1269"}, {"groupId": "OG001", "value": "0.1094", "lowerLimit": "0.0855", "upperLimit": "0.1391"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A marginal logistic regression model with a generalized estimating approach was analyzed using treatment, visit, treatment\\*visit, age group (\\<12 years, \\>=12 years) and region (west: DEU, ESP, FRA, GBR and USA; central: POL; east: BGR, HUN and RUS) as fixed factors. Baseline visit is included as a covariate. No missing data approach was applied.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4146", "statisticalMethod": "Marginal logistic regression", "paramType": "Odds Ratio (OR)", "paramValue": "0.8477", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "1.26", "estimateComment": "12 SQ-HDM SLIT-tablet as the numerator and placebo SLIT-tablet as the denominator."}]}, {"type": "SECONDARY", "title": "Percentage Predicted FEV1", "description": "The outcome measure (by treatment) is an average of the percentage predicted FEV1 measured at visits 5 to 11 (every 4 months during the 20 months efficacy assessment period), analyzed using MMRM (mixed-effect model repeated measurement).\n\nFEV1 (forced expired volume in 1 second) is assessed by use of spirometry and is a measure for lung function. Percentage predicted FEV1 is derived from the predicted FEV1, which is the expected value of FEV1 for a person of a certain age, race, height and gender with healthy lungs.", "populationDescription": "Participants from the full analysis set with observations in the efficacy assessment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage predicted FEV1", "timeFrame": "Efficacy assessment period was 20 months (following a 4-10 months treatment initiation and maintenance period)", "groups": [{"id": "OG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "OG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "254"}, {"groupId": "OG001", "value": "259"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "97.17", "lowerLimit": "96.02", "upperLimit": "98.32"}, {"groupId": "OG001", "value": "97.05", "lowerLimit": "95.82", "upperLimit": "98.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A 'mixed-effect model repeated measurement' model was analysed using treatment, visit, treatment\\*visit, age group (\\<12 years, \\>=12 years) and region (west: DEU, ESP, FRA, GBR and USA; central: POL; east: BGR, HUN and RUS) as fixed factors. Baseline visit was included as a covariate. No missing data approach was applied.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8829", "statisticalMethod": "Mixed-effect model repeated measurement", "paramType": "Mean Difference (Final Values)", "paramValue": "0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.47", "ciUpperLimit": "1.70", "estimateComment": "12 SQ-HDM - placebo"}]}, {"type": "SECONDARY", "title": "Global Evaluation of Allergic Asthma as Having an Improved Outcome", "description": "At the end of trial visit, the subject was asked, when compared to their asthma before IMP treatment, how they felt overall. Subjects who answered 'much better' or 'better' were categorized as having improved allergic asthma. At the end of trial visit, subjects had been treated for 24-30 months (including a 4-10 months treatment initiation and maintenance period).\n\nThe outcome measure (by treatment) is an adjusted odds of experiencing improved allergic asthma.", "populationDescription": "Participants from the full analysis set with observations in the efficacy assessment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Odds of improved allergic asthma", "timeFrame": "Assessment done at the end of trial visit (after 24-30 months of treatment)", "groups": [{"id": "OG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "OG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.66", "lowerLimit": "8.30", "upperLimit": "25.89"}, {"groupId": "OG001", "value": "6.48", "lowerLimit": "4.03", "upperLimit": "10.43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The odds of having an improved outcome was analyzed using a generalized linear mixed model (GLMM) with a logit link function. The model included treatment, age group (\\<12 years, \\>=12 years) and region (west: DEU, ESP, FRA, GBR and USA; central: POL; east: BGR, HUN and RUS) as fixed factors. No missing data approach was applied.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0044", "statisticalMethod": "Generalised linear mixed model", "paramType": "Odds Ratio (OR)", "paramValue": "2.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.29", "ciUpperLimit": "3.96", "estimateComment": "12 SQ-HDM SLIT-tablet as the numerator and placebo SLIT-tablet as the denominator."}]}, {"type": "SECONDARY", "title": "Global Evaluation of Allergic Rhinitis as Having an Improved Outcome", "description": "At the end of trial visit, the subject was asked, when compared to their rhinitis before IMP treatment, how they felt overall. Subjects who answered 'much better' or 'better' were categorized as having improved allergic rhinitis. At the end of trial visit, subjects had been treated for 24-30 months (including a 4-10 months treatment initiation and maintenance period).\n\nThe outcome measure (by treatment) is an adjusted odds of experiencing improved allergic rhinitis.", "populationDescription": "Participants from the full analysis set with observations in the efficacy assessment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Odds of improved allergic rhinitis", "timeFrame": "Assessment done at the end of trial visit (after 24-30 months of treatment)", "groups": [{"id": "OG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)"}, {"id": "OG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.29", "lowerLimit": "5.35", "upperLimit": "12.85"}, {"groupId": "OG001", "value": "5.11", "lowerLimit": "3.49", "upperLimit": "7.48"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The odds of having an improved outcome was analysed using a generalised linear mixed model (GLMM) with a logit link function. The model included treatment, age group (\\<12 years, \\>=12 years) and region (west: DEU, ESP, FRA, GBR and USA; central: POL; east: BGR, HUN and RUS) as fixed factors. No missing data approach was applied.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0698", "statisticalMethod": "Generalised linear mixed model", "paramType": "Odds Ratio, log", "paramValue": "1.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.96", "ciUpperLimit": "2.74", "estimateComment": "12 SQ-HDM SLIT-tablet as the numerator and placebo SLIT-tablet as the denominator."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Allergic Rhinitis Symptoms", "description": "Allergic rhinitis symptoms were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months, for up to 24-30 months.", "reportingStatus": "NOT_POSTED", "timeFrame": "The efficacy assessment period for the endpoint started 4 months after treatment initiation and lasted until the end of the trial or discontinuation of treatment (up to 24-30 months of treatment).", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Allergic Rhinitis Medication Use", "description": "Allergic rhinitis medication use were entered in an eDiary by the participant/caregiver in a 2-week period every 4 months, for up to 24-30 months.", "reportingStatus": "NOT_POSTED", "timeFrame": "The efficacy assessment period for the endpoint started 4 months after treatment initiation and lasted until the end of the trial or discontinuation of treatment (up to 24-30 months of treatment).", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "AEs were collected from consent to last follow-up phone contact (up to 24-30 months of treatment).", "description": "Treatment emergent AEs (TEAEs) are displayed (these were AEs starting on/after time of first IMP and no later than 7 days after last day of IMP). For the first 28 days of treatment, the presence/absence of 15 specific symptoms, identified as local side effects of sublingual immunotherapy (solicited events), were captured in an eDiary. Solicited events were evaluated by the investigator and reported in the eCRF as AEs as per their discretion. TEAEs from the eCRF are included in TEAEs presented.", "eventGroups": [{"id": "EG000", "title": "HDM SLIT-tablet (12 SQ-HDM)", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily HDM sublingual allergy immunotherapy tablet (12 SQ-HDM)", "deathsNumAffected": 0, "deathsNumAtRisk": 270, "seriousNumAffected": 14, "seriousNumAtRisk": 270, "otherNumAffected": 250, "otherNumAtRisk": 270}, {"id": "EG001", "title": "Placebo SLIT-tablet", "description": "Participant's daily background asthma medication of low dose ICS plus LABA or medium/high dose ICS with or without LABA, reliever asthma medication of SABA as needed plus 1 daily placebo sublingual allergy immunotherapy tablet", "deathsNumAffected": 0, "deathsNumAtRisk": 263, "seriousNumAffected": 12, "seriousNumAtRisk": 263, "otherNumAffected": 228, "otherNumAtRisk": 263}], "seriousEvents": [{"term": "Lymphadenitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Eosinophilic oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Pancreatic disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 263}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Infectious mononucleosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 263}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 263}]}, {"term": "Rhinovirus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 263}]}, {"term": "Salmonellosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Skin wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Type 1 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 263}]}, {"term": "Growth retardation", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Scoliosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Anorexia nervosa", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 263}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 263}]}, {"term": "Testicular cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 263}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 263}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 263}]}], "otherEvents": [{"term": "Ear pruritus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 257, "numAffected": 104, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 124, "numAffected": 60, "numAtRisk": 263}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 14, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 263}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 231, "numAffected": 118, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 194, "numAffected": 101, "numAtRisk": 263}]}, {"term": "Aphthous ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 16, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 28, "numAffected": 17, "numAtRisk": 263}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 96, "numAffected": 60, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 77, "numAffected": 51, "numAtRisk": 263}]}, {"term": "Glossodynia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 134, "numAffected": 74, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 23, "numAffected": 18, "numAtRisk": 263}]}, {"term": "Lip swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 154, "numAffected": 71, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 18, "numAffected": 14, "numAtRisk": 263}]}, {"term": "Mouth swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 159, "numAffected": 67, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 16, "numAffected": 11, "numAtRisk": 263}]}, {"term": "Mouth ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 44, "numAffected": 26, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 17, "numAffected": 16, "numAtRisk": 263}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 167, "numAffected": 85, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 96, "numAffected": 57, "numAtRisk": 263}]}, {"term": "Oral pruritus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 475, "numAffected": 175, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 126, "numAffected": 65, "numAtRisk": 263}]}, {"term": "Swollen tongue", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 98, "numAffected": 55, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 263}]}, {"term": "Tongue ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 34, "numAffected": 19, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 15, "numAffected": 9, "numAtRisk": 263}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 49, "numAffected": 33, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 19, "numAffected": 14, "numAtRisk": 263}]}, {"term": "Corona virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 18, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 14, "numAffected": 14, "numAtRisk": 263}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 110, "numAffected": 63, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 95, "numAffected": 57, "numAtRisk": 263}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 21, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 21, "numAffected": 15, "numAtRisk": 263}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 38, "numAffected": 26, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 31, "numAffected": 25, "numAtRisk": 263}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 18, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 22, "numAffected": 18, "numAtRisk": 263}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 120, "numAffected": 54, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 68, "numAffected": 44, "numAtRisk": 263}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 16, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 263}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 158, "numAffected": 80, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 176, "numAffected": 96, "numAtRisk": 263}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 15, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 24, "numAffected": 20, "numAtRisk": 263}]}, {"term": "Pharyngeal oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 113, "numAffected": 58, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 23, "numAffected": 14, "numAtRisk": 263}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 16, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 47, "numAffected": 23, "numAtRisk": 263}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 494, "numAffected": 166, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 178, "numAffected": 94, "numAtRisk": 263}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 12, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 19, "numAffected": 17, "numAtRisk": 263}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 12, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 29, "numAffected": 21, "numAtRisk": 263}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 12, "numAtRisk": 270}, {"groupId": "EG001", "numEvents": 16, "numAffected": 14, "numAtRisk": 263}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Enrollment was paused at the outbreak of the COVID-19 pandemic. During the COVID-19 pandemic the asthma exacerbation rate decreased both in the trial population (blinded data) and in the general asthma population. It was therefore deemed difficult to recruit participants based on a history of recent asthma exacerbations. The sponsor decided to end the trial with the completed participants on 10-Aug-2022 due to the severe impact of COVID-19."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor shall be able to review any proposed publication or presentation at least 60 days in advance of submission. Sponsor cannot require changes. Upon sponsor's request, the investigator shall delay a publication or presentation for 6 months to permit the sponsor to take necessary steps to protect confidential information. For this multi-site trial it is mandatory that the primary publication is based on data from all trial sites analyzed as stipulated in the protocol and in the SAP."}, "pointOfContact": {"title": "Senior Director Global Clinical Development", "organization": "ALK-Abell\u00f3 A/S", "email": "clinicaltrials@alk.net", "phone": "0045 45747576"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-02-18", "uploadDate": "2023-05-26T02:46", "filename": "Prot_000.pdf", "size": 5364345}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-08-11", "uploadDate": "2023-05-26T02:47", "filename": "SAP_001.pdf", "size": 6190544}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-06-23", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000001249", "term": "Asthma"}, {"id": "D000065631", "term": "Rhinitis, Allergic"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M30545", "name": "Rhinitis, Allergic", "asFound": "Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M2853", "name": "Immunomodulating Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}